Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.47588
Abstract: This cohort study investigates serum neurofilament light concentration as a biomarker associated with disability progression in multiple sclerosis in the absence of acute inflammation. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.3596
Abstract: This cohort study uses data from the Chicago Health and Aging Project to examine associations between physical activity and cognitive decline by serum concentrations of neurofilament light (NfL) chain among older adults. read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2020.4986
Abstract: Key Points Question What is the potential of blood-based biomarkers for predicting and monitoring the progression of Alzheimer disease neurodegeneration? Findings In this cohort study that included 1113 participants from the multicentric Alzheimer’s Disease Neuroimaging… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2023.0394
Abstract: This Viewpoint describes the benefits and limitations of using neurofilament light chain (NfL) as a marker of real-time disease activity and treatment response in multiple sclerosis. read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51355
Abstract: We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51518
Abstract: While the anticipated rise of disease‐modifying therapies calls for reliable trial outcome parameters, fluid biomarkers are lacking in spastic paraplegia type 4 (SPG4), the most prevalent form of hereditary spastic paraplegia. We therefore investigated serum… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51522
Abstract: Both retinal atrophy measured through optical coherence tomography and plasma neurofilament light chain (NfL) levels are markers of neurodegeneration, but their relationship is unknown. Therefore, we assessed their determinants and association in 4369 participants of… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51524
Abstract: To develop an age‐adjustment model for neurofilament light chain (NfL), an emerging injury marker in patients with a range of neurologic conditions including multiple sclerosis (MS). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51622
Abstract: Estrogens have neuroprotective actions depending on estrogen type, dose, and timing in both preclinical models and in women during health and disease. Serum neurofilament light chain is a putative biomarker of neurodegeneration in multiple sclerosis,… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51676
Abstract: Interpretation of axonal damage biomarker Neurofilament Light chain (NfL) concentrations is difficult due to the lack of age‐specific and disease‐specific reference values. We here developed an interactive interface to support interpretation of NfL results in… read more here.